IGC Pharma, Inc. (IGC)
0.3063
0.00 (0.00%)
USD |
NYAM |
Aug 26, 16:00
0.3063
0.00 (0.00%)
After-Hours: 19:10
IGC Pharma EPS Diluted (Quarterly) : -0.0293 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0293 |
| March 31, 2026 | -0.0245 |
| December 31, 2025 | -0.0077 |
| September 30, 2025 | -0.0201 |
| June 30, 2025 | -0.0193 |
| March 31, 2025 | -0.0157 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | -0.0226 |
| June 30, 2024 | -0.0327 |
| March 31, 2024 | -0.0436 |
| December 31, 2023 | -0.0877 |
| September 30, 2023 | -0.0451 |
| June 30, 2023 | -0.0391 |
| March 31, 2023 | -0.0759 |
| December 31, 2022 | -0.0424 |
| September 30, 2022 | -0.0468 |
| June 30, 2022 | -0.054 |
| March 31, 2022 | -0.1274 |
| December 31, 2021 | -0.0466 |
| September 30, 2021 | -0.087 |
| June 30, 2021 | -0.0373 |
| March 31, 2021 | -0.0667 |
| December 31, 2020 | -0.0562 |
| September 30, 2020 | -0.0402 |
| June 30, 2020 | -0.0468 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.08 |
| December 31, 2019 | -0.0405 |
| September 30, 2019 | -0.0298 |
| June 30, 2019 | -0.0349 |
| March 31, 2019 | -0.04 |
| December 31, 2018 | -0.0292 |
| September 30, 2018 | -0.03 |
| June 30, 2018 | -0.02 |
| March 31, 2018 | -0.02 |
| December 31, 2017 | -0.0189 |
| September 30, 2017 | -0.01 |
| June 30, 2017 | -0.02 |
| March 31, 2017 | -0.03 |
| December 31, 2016 | -0.004 |
| September 30, 2016 | -0.02 |
| June 30, 2016 | -0.02 |
| March 31, 2016 | -0.08 |
| December 31, 2015 | -0.02 |
| September 30, 2015 | -0.04 |
| June 30, 2015 | -0.03 |
| March 31, 2015 | -0.1299 |
| December 31, 2014 | -0.05 |
| September 30, 2014 | -0.07 |
| June 30, 2014 | -0.12 |
| March 31, 2014 | -0.1561 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -0.2295 |
| CNBX Pharmaceuticals, Inc. | -0.0001 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 2.578 |
| Fulcrum Therapeutics, Inc. | -0.3433 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.936M |
| Revenue (Quarterly) | 0.265M |
| Total Expenses (Quarterly) | 3.201M |
| Enterprise Value | 31.92M |
| Gross Profit Margin (Quarterly) | 2.64% |
| Profit Margin (Quarterly) | -1.11K% |
| Earnings Yield | -26.64% |
| Normalized Earnings Yield | -26.64 |